Prescription medication · Tetracycline Antibiotic

omadacycline

Also sold as Nuzyra. Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.

Data updated 2026-05-15

1,476
FDA reportsRarely reported
1
InteractionFew interactions
Rx
Availability

What the data shows

omadacycline (Nuzyra) is a prescription Tetracycline Antibiotic, among the least-reported drugs the FDA tracks (1,476 FDA reports), with 1 documented drug interaction.

Reporting volume reflects how widely a drug is used and studied, not how dangerous it is, a FAERS report documents a temporal association, never proof of cause.

omadacycline (Nuzyra) is a prescription Tetracycline Antibiotic. Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.

Nuzyra is an antibiotic medicine. It fights certain bacteria to treat infections.

View Alternatives → Compare with Another Drug → Full Side Effects Report →

What it does

Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.

Common side effects

Nausea, Vomiting, Reactions where the IV was given

Key warnings

Nuzyra may cause an imbalance in the number of deaths in patients with pneumonia.

The sections below are summarized in plain English from omadacycline's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.

How It Works

Nuzyra is a tetracycline antibiotic. It stops bacteria from growing by interfering with their protein production. This helps your body fight off the infection.

Side Effects (from patient reports)

Based on 1,476 FDA adverse event reports.

Most-reported reactions

Adverse reactions in FAERS for omadacycline, by number of reports

reports

What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.

Source FDA Adverse Event Reporting System (FAERS) As of 2025

Reports over time

Adverse-event reports filed for omadacycline each year to the FDA Adverse Event Reporting System (FAERS).

0100200300400500 20172019202020212022202320242025 391

Year-to-year volume tracks usage, prescribing, and scrutiny, not a change in per-patient risk. Source: FDA FAERS.

Where omadacycline sits

omadacycline has more FDA adverse-event reports than 9% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.

fewest reports most reports

Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is omadacycline; the line is the median (50th percentile).

FDA Adverse Event Report Analysis

Detailed analysis of 1,476 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2017–2025.

Total Reports

1,476

Reports Mentioning Death

101

6.8% of reports — not proof of cause

Hospitalization Reports

329

Top Indication

Mycobacterium Abscessus Infection

Gender Distribution

Female 730 (55%)
Male 590 (45%)

Age Distribution

0–17 40
18–44 139
45–64 330
65–74 200
75+ 199

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
2 NAUSEA 245
3 VOMITING 152
5 DIARRHOEA 107
6 INCORRECT PRODUCT ADMINISTRATION DURATION 76
7 RASH 70
8 INCORRECT DOSE ADMINISTERED 68
9 DEATH 66
10 DYSPNOEA 65
11 FATIGUE 56
12 HOSPITALISATION 55
13 HEADACHE 52
14 PRURITUS 52
15 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 48
16 COUGH 44
18 ASPARTATE AMINOTRANSFERASE INCREASED 41

Reactions in Death Reports

DEATH 65
PNEUMONIA 11
DYSPNOEA 7
THERAPY INTERRUPTED 7
COUGH 6
HOSPITALISATION 6
WEIGHT DECREASED 6
DRUG DOSE TITRATION NOT PERFORMED 5
DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 5
LUNG DISORDER 5

Reactions in Hospitalization Reports

HOSPITALISATION 55
NAUSEA 37
DYSPNOEA 31
INCORRECT PRODUCT ADMINISTRATION DURATION 26
COUGH 24
THERAPY INTERRUPTED 23
VOMITING 23
CONDITION AGGRAVATED 22
PNEUMONIA 22
FATIGUE 17

Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Nuzyra may cause an imbalance in the number of deaths in patients with pneumonia. The cause of this is not known, so your doctor will watch you closely. Nuzyra can also cause tooth discoloration and affect bone growth in children under 8 and unborn babies. Diarrhea can occur, so tell your doctor if you have diarrhea while taking Nuzyra.

Known Drug Interactions

( 7.1 ) Absorption of tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate and iron containing preparations. 7.2 Antacids and Iron Preparations Absorption of oral tetracyclines, including NUZYRA, is impaired by antacids containing aluminum, calcium, or magnesium, bismuth subsalicylate, and iron containing preparations [see Dosage and Administration (2.1) ].

Mechanism: Bismuth subsalicylate interferes with how your body takes in the antibiotic, making the medicine less effective at fighting infection.

This is a plain-language summary of FDA-label interaction records and does not provide individual medication-combination directions.

Common Questions

What should I avoid while taking Nuzyra?
Avoid dairy products, antacids, and multivitamins for 4 hours after taking the pill.
Can I take Nuzyra with food?
Take Nuzyra tablets on an empty stomach, at least 4 hours after eating. After taking the pill, wait 2 hours before eating.
How long will I need to take Nuzyra?
The usual treatment time is 7 to 14 days.
What if I feel better before finishing all my Nuzyra?
Take Nuzyra for the full treatment time, even if you feel better. Stopping early may cause the infection to come back.
Can Nuzyra affect my teeth?
Nuzyra can cause permanent tooth discoloration if taken during tooth development (pregnancy to age 8).
Can Nuzyra affect my bones?
Nuzyra can temporarily slow bone growth if taken during pregnancy or in children under 8.
What should I do if I get diarrhea while taking Nuzyra?
Tell your doctor if you develop diarrhea while taking Nuzyra.
Can I take antacids with Nuzyra?
No, avoid antacids for 4 hours after taking Nuzyra tablets.
Will Nuzyra interact with other medications I'm taking?
Nuzyra can interact with blood thinners, so your doctor may need to adjust your dose. Also, antacids and iron supplements can affect how well Nuzyra works.
What happens if I take too much Nuzyra?
Call your doctor or seek medical attention immediately.
What are the common side effects of omadacycline?
The registry lists Nausea, Vomiting, Reactions where the IV was given, Increased liver enzyme levels, High blood pressure among the most-reported FAERS reaction terms for omadacycline. The compiled record contains 1,476 FDA adverse-event reports. These counts are not an individual symptom assessment.
Does omadacycline interact with other medications?
The registry has 1 documented interaction rows for omadacycline. Notable source-record pairings include bismuth subsalicylate. These rows are not a complete medication review.
What drug class is omadacycline?
omadacycline belongs to the Tetracycline Antibiotic drug class. It requires a prescription (Rx). Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection.
What pregnancy or breastfeeding source fields are listed for omadacycline?
The FDA label for omadacycline contains product-specific pregnancy or breastfeeding language. PlainMeds does not apply that source text to an individual.

Other drugs grouped near omadacycline - same-class peers and common alternatives.

Compare omadacycline vs amikacin side-by-side →

Compare beyond drug class

Nationwide peers by FAERS volume & death-report share

Two PlainMeds-derived comparison paths for omadacycline: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.

Medication Guides

Save on omadacycline

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for omadacycline

The FDA label for omadacycline (sold under brand names such as Nuzyra) classifies it as a prescription-only medication in the Tetracycline Antibiotic class. Nuzyra treats community-acquired bacterial pneumonia (CABP), a lung infection. Official labeling lists 9 commonly reported side effects, including Nausea, Vomiting, Reactions where the IV was given.

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 1,476 voluntary reports. The database also lists 1 documented drug interaction derived from FDA labeling, with the top-flagged interaction rated minor severity. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.

Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.

Last updated: March 31, 2025

PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.

Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.

All federal data sources used on this page